Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_4
1
20%
Ph phase_1
2
40%
Ph phase_3
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

unknown120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents

NCT04884685
completedphase_1

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

NCT05228613
completedphase_3

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

NCT04651790
completedphase_1

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

NCT05067894
unknownphase_4

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

NCT04962308

Clinical Trials (5)

Showing 5 of 5 trials
NCT04884685Phase 2

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents

Completed
NCT05228613Phase 1

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

Completed
NCT04651790Phase 3

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

Completed
NCT05067894Phase 1

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

Completed
NCT04962308Phase 4

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5